Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Thermal Cycler

By Drug Discovery Trends Editor | May 18, 2010

Fluidigm Corporation introduced its FC1 Cycler designed to reduce the thermal cycling time by a factor of three when compared with the company’s current products. The FC1 Cycler can reduce overall system configuration costs for customers conducting high sample throughput SNP genotyping since they will need fewer thermal cyclers to achieve their output requirements.

Adding the new FC1 Cycler to today’s existing Fluidigm system offering provides users with the ability to double the number of microfluidic chips that can be processed in a single day. This ultra-fast thermal cycler provides a foundation for future groundbreaking Fluidigm products intended to dramatically boost productivity and lower costs for customers conducting high sample throughput genotyping.

“High throughput SNP genotyping programs are embracing Fluidigm technology. To bring even greater value to our SNP genotyping customers, we are creating new instrumentation and revolutionary chip architectures to transform this market segment over the next 12 months. Fluidigm’s new FC1 Cycler is the first of these new products to roll out,” said Gajus Worthington, president and chief executive officer, Fluidigm.

In addition to the fast thermal cycling capability, the FC1 Cycler integrates a self-contained vacuum source and touch screen interface (that offers easy editing of thermal protocols) in a streamlined design that minimizes lab space requirements while maximizing productivity.

The new FC1 Cycler is fully compatible with Fluidigm’s 96.96 and 48.48 Dynamic Array IFCs and its 12.765 Digital Array IFC. The FC1 Cycler, combined with either the Fluidigm EP1 Reader or BioMark Real-time PCR System, can complete the entire workflow of the system in a matter of hours with only minutes of hands-on time for loading the chips. This is compared to days of hands-on time and weeks of effort to complete this volume of work using traditional 384-well plates.

Fluidigm Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE